Tags

Type your tag names separated by a space and hit enter

An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).
Expert Opin Ther Pat. 2017 Mar; 27(3):311-345.EO

Abstract

INTRODUCTION

Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011-2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme.

Authors+Show Affiliations

a Department of Pharmaceutical Chemistry , ISF College of Pharmacy , Moga , India.b Department of Pharmacy , Rayat-Bahara group of Institutes , Hoshiarpur , India.c Department of Pharmacy , DIT University , Dehradun , India.d Department of Pharmaceutical Sciences , Guru Nanak Dev University , Amritsar , India.d Department of Pharmaceutical Sciences , Guru Nanak Dev University , Amritsar , India.a Department of Pharmaceutical Chemistry , ISF College of Pharmacy , Moga , India.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27841045

Citation

Ojha, Ritu, et al. "An Updated Patent Review: Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia and Gout (2011-2015)." Expert Opinion On Therapeutic Patents, vol. 27, no. 3, 2017, pp. 311-345.
Ojha R, Singh J, Ojha A, et al. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opin Ther Pat. 2017;27(3):311-345.
Ojha, R., Singh, J., Ojha, A., Singh, H., Sharma, S., & Nepali, K. (2017). An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opinion On Therapeutic Patents, 27(3), 311-345. https://doi.org/10.1080/13543776.2017.1261111
Ojha R, et al. An Updated Patent Review: Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia and Gout (2011-2015). Expert Opin Ther Pat. 2017;27(3):311-345. PubMed PMID: 27841045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). AU - Ojha,Ritu, AU - Singh,Jagjeet, AU - Ojha,Anu, AU - Singh,Harbinder, AU - Sharma,Sahil, AU - Nepali,Kunal, Y1 - 2016/11/28/ PY - 2016/11/15/pubmed PY - 2017/3/11/medline PY - 2016/11/15/entrez KW - Xanthine oxidase inhibitors KW - allopurinol KW - febuxostat KW - gout KW - non purine KW - purine SP - 311 EP - 345 JF - Expert opinion on therapeutic patents JO - Expert Opin Ther Pat VL - 27 IS - 3 N2 - INTRODUCTION: Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011-2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme. SN - 1744-7674 UR - https://www.unboundmedicine.com/medline/citation/27841045/An_updated_patent_review:_xanthine_oxidase_inhibitors_for_the_treatment_of_hyperuricemia_and_gout__2011_2015__ L2 - http://www.tandfonline.com/doi/full/10.1080/13543776.2017.1261111 DB - PRIME DP - Unbound Medicine ER -